Revatis S.A. • Regenerative Medicine and Cell Therapy

The growth of Revatis is supported by its innovative and patented technology to obtain multipotent adult mesenchymal stem cells from a minimally invasive muscle micro-biopsy

Mission, values & team

Innovation in cellular therapy

Revatis is a Spin Off from the University of Liège, dedicated to regenerative medicine and cell therapy. Revatis is based on the scientific discoveries of Prof. D. Serteyn and Dr J. Ceusters and has solid intellectual property and exceptional know-how.

Revatis has a patented technology for obtaining multipotent stem cells from a muscle micro-biopsy. This technology is available for clinical applications in veterinary medicine and for research in human medicine.

In veterinary medicine, Revatis aims to produce autologous stem cells for therapeutic use in horses and companion animals. In human medicine, Revatis is positioning itself as a supplier of personalized stem cells for banking, research, organ-on-a-chip and 3D bioprinting.

GMP certified production

The production of stem cells complies with the standards of good manufacturing practices (GMP) essential for perfect traceability and immediate or deferred clinical use. The production is carried out in an" aseptic isolator "specifically adapted to Revatis protocols

Technologies
Signature of Didier Serteyn

Didier Serteyn

CEO Revatis

Research and clinical application

Revatis bridges the gap between research and clinical uses of cell therapy and regenerative medicine.

  • R&D centers in cell therapy
  • Companies dedicated to 3D bioprinting
  • Companies dedicated to organs on a chip
  • Veterinarians
  • Specialist clinicians
  • Breeders
  • Owners
  • Trainers
  • Riders

International development

Focused on the entire Europe, Revatis has also developed partnerships in the United States, the United Arab Emirates and Australia.

Partnerships
World map

Actualities

Read the articl

Participation of Revatis in the BIO congress

Read the articl

Sending of Revatis cells to Australia

Read the articl

New IP publications in US

All the articles
Frequently asked questions

Frequently asked questions

Do not hesitate to contact us for any questions about our range of products and services.